Peptides in Weight Management Research: Semaglutide, Tirzepatide, and Retatrutide Compared

The incretin class of peptides has generated more mainstream attention than perhaps any other category of research compounds in the past decade. Semaglutide, tirzepatide, and retatrutide — representing mono-agonist, dual-agonist, and triple-agonist approaches respectively — have been studied extensively in clinical trials focused on metabolic function and body composition.

This article provides a factual overview of all three compounds, their mechanisms, and how they compare based on published clinical trial data.

The Incretin System

To understand why these peptides have generated so much research interest, it helps to understand the incretin system. Incretins are gut hormones released after eating that stimulate insulin secretion and influence appetite regulation. The two primary incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

In healthy metabolism, these hormones help regulate blood sugar, signal satiety, and influence how the body processes nutrients. Research into synthetic analogs of these hormones — peptides that mimic or enhance their effects — has become one of the most active areas of biomedical investigation.

Semaglutide: The GLP-1 Mono-Agonist

Semaglutide activates one receptor — GLP-1. It was the first incretin-based peptide to generate widespread public attention, driven by large-scale clinical trial programs that studied its effects on body weight and metabolic parameters.

Published clinical trial data has reported mean body weight reductions of approximately 15% from baseline at 68 weeks in research subjects receiving the highest studied doses. The compound's extended half-life of approximately one week — achieved through albumin-binding modifications — enables once-weekly dosing in research protocols.

Semaglutide has a molecular weight of approximately 4113.58 g/mol and a CAS number of 910463-68-2.

Tirzepatide: The Dual GIP/GLP-1 Agonist

Tirzepatide represents the next evolution — activating both GIP and GLP-1 receptors simultaneously. This dual mechanism has been associated with enhanced metabolic effects compared to GLP-1 mono-agonists in published head-to-head comparison data.

The SURPASS and SURMOUNT clinical trial programs studied tirzepatide across multiple doses and populations. Published results have reported mean body weight reductions of approximately 20-22% from baseline at the highest studied doses — exceeding published results for semaglutide at comparable timepoints.

Tirzepatide has a molecular weight of approximately 4813.45 g/mol and a CAS number of 2023788-19-2.

Retatrutide: The Triple GLP-1/GIP/Glucagon Agonist

Retatrutide adds a third receptor — glucagon — to the dual-agonist approach. The glucagon receptor is associated with thermogenesis and energy expenditure, which is a mechanism not engaged by either semaglutide or tirzepatide.

A Phase 2 clinical trial published in the New England Journal of Medicine in 2023 reported mean body weight reductions of approximately 24% at 48 weeks at the highest studied dose. This exceeded published results for both semaglutide and tirzepatide at comparable timepoints, though direct comparison is limited by differences in trial design and patient populations. Phase 3 trials are currently underway.

Retatrutide has a CAS number of 2381089-83-2.

Comparative Overview

The progression from mono-agonist to dual-agonist to triple-agonist represents an expansion of the number of metabolic pathways being engaged simultaneously. Each successive generation has been associated with greater effects in published clinical data, though it is important to note that direct head-to-head trials between all three compounds have not been conducted.

Semaglutide engages one receptor (GLP-1), tirzepatide engages two (GIP and GLP-1), and retatrutide engages three (GLP-1, GIP, and glucagon). Each additional receptor adds complementary mechanisms that may contribute to the differences observed in clinical trial outcomes.

Research Considerations

All three compounds are available from Durham Peptides as lyophilized research peptides requiring reconstitution with bacteriostatic water. Each is Janoshik tested with independently verifiable COAs.

For a detailed comparison of semaglutide and tirzepatide specifically, see our article: Semaglutide vs Tirzepatide: What's the Difference?

Selected Research References

• Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021. PMID: 33567185

• Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM. 2022. PMID: 35658024

• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." NEJM. 2023. PMID: 37366315

All products mentioned in this article are sold by Durham Peptides for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.